Ladies and gentlemen, thank you for standing by, and welcome to the Runway Growth Finance Q4 and Fiscal Year Ended 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Quinlan Abel, Assistant Vice President, Investor Relations. Please go ahead. Thank you, operator. Good evening, everyone, and welcome to the Runway Growth Finance conference call for the Q4 and fiscal year ended December 31, 2025. Joining us on the call today from Runway Growth Finance are David Spreng, Chief Executive Officer, Greg Greifeld, Chief Investment Officer of Runway Growth Capital LLC, our investment advisor, and Tom Raterman, Chief Financial Officer and Chief Operating Officer. Runway Growth Finance's Q4 and fiscal year ended 2025 financial results were released just after today's market close and can be accessed from Runway Growth Finance's investor relations website at investors.runwaygrowth.com. We have arranged for a replay of the call to be available on the Runway Growth Finance webpage. During this call, I want to remind you that we may make forward-looking statements based on current expectations. The statements on this call that are not purely historical are forward-looking statements. These forward-looking statements are not a guarantee of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements, including, without limitation, market conditions caused by uncertainties surrounding interest rates, changing economic conditions, and other factors we identify in our filings with the SEC. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions can prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions can be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained on this call are made as of the date hereof, and Runway Growth Finance assumes no obligation to update the forward-looking statements or subsequent events. To obtain copies of SEC-related filings, please visit our website. With that, I will turn the call over to David. Thank you, Quinlan. Thanks, everyone, for joining us this evening to discuss our Q4 and Full Year 2025 Financial Results. Today, I'll discuss our highlights for the quarter and the year and provide an update on our pending acquisition of SWK Holdings. Greg will discuss our portfolio activity and share our outlook on the current market backdrop, and Tom will conclude with a deep dive into our financial performance. In the Q4, Runway delivered total investment income of $30 million and net investment income of $11.6 million. During the quarter, we completed 7 investments in new and existing portfolio companies across the high-growth verticals of technology, healthcare, and select consumer sectors, representing $42.9 million in funded loans. Taking a step back, 2025 was a dynamic year shaped by several market-moving events and volatility, including ongoing tariff uncertainty, evolving interest rate policy, geopolitical conflicts, and increasing attention to AI-driven disruption. In times like these, it's critical to stay disciplined in our investment process and diligent in our approach to portfolio construction, traits that have defined our company since its founding. We believe our consistent performance across cycles reflects this philosophy. That said, we are not complacent and remain focused on executing against the initiatives we have discussed in recent quarters, which include further enhancing the risk profile of our portfolio through diversification and smaller position sizes, expanding our suite of financing solutions, and maximizing the value of our existing commitments through robust monitoring and diligent risk mitigation. As a part of the BC Partners credit ecosystem, we've made steady progress on these objectives. We've also leveraged their combined resources and network in evaluating attractive and complementary portfolios, as demonstrated by our announced acquisition of SWK Holdings in the Q4. As an update on timing, the transaction with SWK is now expected to close in early April. Our confidence in closing this transaction remains unchanged. One key aspect of our transaction with SWK is the diversification it will bring to our portfolio. While we remain confident in our current asset mix, increasing our exposure and strengthening our capabilities in healthcare and life sciences will enhance our portfolio and drive optionality moving forward. In the coming quarters, we believe there could be attractive opportunities across all of our areas of focus, technology, healthcare, and select consumer sectors. Greg will provide additional detail on how we think about software investing, with the takeaway being we have strong conviction in our underwriting capabilities and disciplined investment framework, which we believe position us well to consistently identify and execute on attractive opportunities in the sector. By broadening exposure across sectors and maintaining an allocation to software companies that meet our high standards, Runway is better positioned to generate consistent, attractive, and risk-adjusted results for our shareholders. Before I turn the call over to Greg, I'll conclude with an update on our originations in the Q1. Although this is seasonally our slowest quarter, activity thus far is encouraging, and our pipeline is stronger than it was at this point last year, giving us measured optimism for the remainder of 2026. As we take advantage of enhanced origination channels through BC Partners and SWK throughout the remainder of the year, we will apply the same rigor to new opportunities and act thoughtfully in making any additions to our portfolio. I will now turn over to Greg for more in-depth look at our portfolio activity. Thank you, David. Tonight, I will recap our portfolio activity during the quarter, provide an update on our progress against our portfolio optimization initiatives, and discuss how we are competitively positioned for the year ahead. Before I turn to our portfolio activity, I think it's important to reiterate some of what David described about our approach in deploying capital. At our core, Runway upholds a credit-first investment discipline with a preference for less economically sensitive business models. Combined with our focus on first lien senior secured investments to late-stage companies, we aim to generate durable growth and attractive returns on a risk-adjusted basis. As it pertains to software specifically, we are confident in our current portfolio and continue to be positive on the sector as an investment opportunity. We believe the best companies will not only be able to coexist with AI but will be able to leverage AI as a tool to optimize their operating models and accelerate penetration in the markets they serve. As our investment team has evaluated deals over the last several years, finding companies that fit this mold has been a key priority. While this is easier said than done, we believe our dedication to process, our deeply experienced team, and our long-standing relationships across the venture ecosystem allow us to identify the right opportunities to grow our portfolio. More specifically, if you look at our existing portfolio, our software companies share the following characteristics, mission-critical functions with a long diligence and implementation cycle, strong moats defined by domain expertise and high switching costs, and customer diversification, which we believe meaningfully de-risks revenue growth projections. Further, the founders we partner with are forward-thinking and always looking for ways to optimize their businesses. This includes using AI to improve operations, lower cost structure, and extend cash runways. From a credit perspective, our software portfolio metrics are on solid footing. The software companies in our portfolio are delivering consistent revenue growth and maintaining stable LTVs. Lastly, we always actively monitor our portfolio companies, remaining in close contact with our borrowers and their sponsors. This allows us to have continued confidence in the outlook for our software portfolio and our portfolio at large. Turning now to our portfolio activity during the Q4. Runway completed 7 investments in new and existing portfolio companies for a total of $42.9 million funded. These investments included completion of a new $20 million investment to a fast-growing mobility company offering a seamless, all-inclusive car subscription service, funding $20 million at close. Completion of a new $10 million investment to a special purpose vehicle formed by an experienced consumer products investor and operator to support their latest investment, funding $10 million at close. Completion of a new $20 million investment to Shield Therapeutics, funding $2 million at close. Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on delivering innovative therapies to address significant unmet needs in patients with iron deficiencies. We also completed follow-on investments with an aggregate amount of $10.9 million to four existing portfolio companies, including Blueshift, Bombora, Autobooks, and Marley Spoon. Looking at the year ahead, we will continue to focus our opportunities to efficiently scale our portfolio while maintaining our defensive profile. We have a strong funnel featuring contributions from BC Partners and expect the pending acquisition of SWK to be additive to our sourcing capabilities, particularly within healthcare. Now, I'll turn the call over to Tom for a review of our financials. Thank you, Greg. Turning now to the Q4 results. We generated total investment income of $30 million and net investment income of $11.6 million in the Q4 of 2025, a decrease compared to $36.7 million and $15.7 million in the Q3 of 2025. Our weighted average portfolio risk rating increased to 2.45 in the Q4 of 2025 compared to 2.42 in the Q3 of 2025. Our rating system is based on a scale of 1 to 5, where 1 represents the most favorable credit rating. Our total investment portfolio had a fair value of $927.4 million, a decrease of 2% from $946 million in the Q3 of 2025. To reiterate, we've structured our portfolio to be comprised almost exclusively of first lien senior secured loans, which reflects our focus on risk mitigation and diligent portfolio management. We delivered $0.32 per share of net investment income in the Q4. our base dividend in the Q4 was $0.33 per share, and at the end of the year we had spillover income of approximately $0.65 per share. Prepayment fee income during the quarter declined sequentially, returning to more normalized levels, which contributed to the decline in NII. For the Q1, we expect a $0.02 headwind related to a one-time charge stemming from the full redemption of our 8% notes and partial redemption of our 7.5% notes, both of which were due in 2027. As we evaluated the SWK transaction, a key benefit was its ability to stabilize our asset base amid recently elevated prepayments and the deliberate portfolio optimization actions we've taken, including exiting or resizing certain positions. We continue to expect this outcome upon closing. However, the modest delay in timing will contribute to some softness in Q1 2026 earnings. With respect to the dividend, we believe it is set at a sustainable level. Our board will continue to evaluate and approve future distributions, knowing how important consistency is to our fellow shareholders. Our debt portfolio generated a dollar weighted average annualized yield of 14.2% for the Q4 of 2025, decreasing from 16.8% quarter-over-quarter and decreasing from 14.7% for the comparable period last year. The sequential decline was the result of lower prepayment income in the quarter. Moving to our expenses, total operating expenses were $18.4 million for the Q4 of 2025, a decrease from $21 million in the Q3 of 2025. We recorded a net realized loss on investments of $377 thousand in the Q4 of 2025 compared to a net realized loss on investments of $1.3 million in the Q3 of 2025. During the Q4, we experienced two full repayments and one partial repayment totaling $60.6 million and scheduled amortization of $2.2 million. As of December 31st, 2025, we had only one loan on non-accrual status, and that is Domingo Healthcare. The loan has a cost basis of $4.8 million and fair market value of $2.4 million or 50% of cost, representing just 0.25% of the total investment portfolio at fair value as of December 31st, 2025. As of December 31st, 2025, Runway had net assets of $484.9 million, decreasing from $489.5 million at the end of the Q3 of 2025. NAV per share was $13.42 at the end of the Q4, a decrease of 1% compared to $13.55 at the end of the Q3 of 2025. At the end of the Q4 of 2025, our leverage ratio and asset coverage were 0.9 and 2.11 times respectively, compared to 0.92 and 2.09 times respectively at the end of the Q3 of 2025. As of December 31st, 2025, our total available liquidity was $395.2 million, including unrestricted cash and cash equivalents, and we had borrowing capacity of $377 million. As of December 31st, 2025, we had a total of $145.5 million in unfunded commitments, which was comprised of $122.8 million to provide debt financing to our portfolio companies and $22.7 million to provide equity financing to our JV with Cadma. Approximately $32.4 million of our unfunded debt commitments are eligible to be drawn based on achieved milestones. Subsequent to quarter end, we took steps to enhance our balance sheet and reduce our cost of funds by launching an underwritten public offering of $103.25 million in aggregate principal amount of unsecured notes due in February 2031 at 7.25%. We also redeemed a portion of our 7.5% notes and all of our 8% notes, which were due in 2027, taking advantage of an attractive rate and spread environment as well as extending our debt maturity ladder. Before we conclude, I'd like to take a moment to reflect on the progress we've made over the last 18 months and reiterate our confidence in the transaction with SWK and its anticipated benefits. Prior to our acquisition by BC Partners, Runway was operating in a venture ecosystem facing a valuation reset and muted sponsor activity, so we intentionally looked for ways to strengthen our competitive position. This included the BC Partners transaction, which has meaningfully widened our deal funnel. Now, the SWK transaction will expand healthcare and life sciences exposure and widen our opportunity set further. Through this process, we've meaningfully enhanced the portfolio's earnings power, optimized portfolio composition, and navigated periods of elevated repayments. At the same time, we're reducing the risk profile of the portfolio. Following the close of the SWK transaction, which should be on or about April 6th, we expect to reduce our average position size to $23.5 million or 2.2% of the portfolio. This compares to $30.3 million or 3.1% of the total portfolio before the BC Partners transaction, marking tangible progress against our portfolio enhancement initiatives. As we've discussed before, other benefits of the transaction include enhancing our financial profile, expanding our shareholder base, generating run rate net investment income accretion in the mid-single digits, and supporting modest ROE expansion as well as improved dividend coverage. In tandem with the enhanced earnings power and lower risk profile the deal brings, we're potentially expanding our access to new debt financing markets, including ABS and other secured lending markets. We look forward to the deal closing in early April. I'll conclude with an update on our capital allocation initiatives. Due to the pending acquisition of SWK, we were not able to utilize our stock repurchase program during the quarter and will not be able to do so until after the transaction closes and we are outside of our normal blackout periods. Our existing stock repurchase program will expire before the blackout window opens. However, in general, we continue to view stock repurchases as an important tool in delivering shareholder value. Finally, on February 25th, 2026, our board declared a regular distribution for the Q1 of 2026 of $0.33 per share. While we face some fluctuation in earnings quarter- to- quarter based on timing of the SWK deal and other factors, we're confident that our earnings power is aligned with the current distribution level on a four-year basis. With that, operator, please open the line for questions. Thank you. To ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Erik Zwick with Lucid Capital Markets. Your line is now open. Thank you. Good afternoon, guys. David, in your prepared comments, you noted that the pipeline is stronger than it was at this point last year. I'm wondering if you or Greg, if you wanted to weigh in as well, could you just talk about maybe, you know, how it looks today in terms of new versus add-on opportunity, you know, if there's any particular industries that are more kind of heavily weighted at this point. You know, I think you mentioned also in the back half of the year that you could see some additional growth from the benefits of BC Partners and SWK and whether you would think that broadens kind of the mix. I think you mentioned some new products as well. Just kind of share with us an outlook there. Yeah. Great. Thanks, Erik. I can start, and then Greg can add on. The comment really represents the impact that BC primarily is having on our deal flow. We're seeing a lot of really interesting opportunities from them, and we've done several deals together already, and I expect we'll do at least one deal together per quarter, going forward. SWK represents a huge opportunity to upsize the loans that they have to their base. On top of that, just our normal deal flow, excluding BC and SWK is pretty strong. I think we do believe that we've got good momentum. That can change at any time, as I think all three of us said in the prepared remarks, is that we're gonna remain conservative in our approach to underwriting, and we're gonna continue to look for the strongest companies. The problem is that when we like something, somebody else usually loves it and offers, you know, very aggressive terms. Unfortunately, we just at some point have to back out and just say, "It's not worth it." There are getting to be some really interesting opportunities with very juicy returns, particularly in software and in consumer. You know, we've never been ones to chase after returns. We'd rather have a slightly lower return that comes with a lot less risk. It is interesting to note that the competitive dynamic in those two sectors is offering pretty good returns. Greg, anything else you wanna add? Yeah, I would definitely echo those sentiments. I think that our core pipeline at the bottom definitely increased year- over- year. One thing I would point to is, there has definitely been uncertainty in the public market, which for us as providers in the private market is a benefit. What I mean by that is, if you look at going into the beginning of the year in terms of potential for IPOs this year, you know, obviously some big blockbusters on the IPO window for companies overall, that seems to not be happening. Which leads to look for alternative solutions, themselves, with that IPO being off the table, has led to an increase in our core pipeline. While SWK has not closed yet, I would say just we've been involved in healthcare since 2020. But this deal that is an inbound opportunity on the healthcare side. That's great color. Thanks, guys. Maybe a question for Tom, just. Do you have a pro forma leverage number for the, you know, after the Q1 actions or is it materially different than it was at 12/31? Just how are you thinking about the appropriate level of leverage today for the portfolio? Yeah. Thanks, Erik. Post SWK will be just under 1.2. We'll each strike our NAV two days before the closing, which should be April 6th. As we think about then moving forward, we still wanna run between 1.2 and 1.3 and consider that our fully levered run rate, if you will. One of the things that we'll consider, and a lot of it will depend on the economic environment and volatility in the capital markets. With the prepayments over the last, call it 18-24 months, we've seen it's very difficult during a portfolio reconstruction period or reset period when we're putting out, you know, smaller amounts on a per deal basis. We might get $60 million back or $50 million back. We wanna put that out in 2 or 3 deals. We may, in the short term, as we have line of sight to either scheduled maturities or anticipated prepayments, we might run a little high one quarter knowing that in the, you know, coming quarter that we're gonna see a prepayment. We wouldn't run generally, you know, purposefully above 1.35 in that scenario. We may, you know, in the short term, try to protect the core earnings power of the portfolio from some of those prepayments. If it's one thing that, you know, we've seen over the last 18-24 months is that it's harder to put that money to work in smaller pieces given the competitive environment and our just overall level of pickiness, choosiness in transactions. That's helpful. Thanks. Last one for me. Just, is there any new updates on the Cadma JV to communicate? We continue to work actively with Cadma. We've got a couple of deals in the JV right now. It's been, again, a little difficult to build that up given the aggregate deal flow. When we sat down recently with our partners at Cadma, I think there's a renewed effort to really build that portfolio and juice up the earnings power there. We do expect the first distribution from the JV in Q2, so you'll see that flow through the Q2 income statement. Great. Thanks for taking my questions today. Thanks, Erik. Our next question comes from the line of Casey Alexander with Compass Point Research & Trading. Your line is now open. Good afternoon. Thanks for taking my questions. Tom, is there any way that you can update us as to like there have been some changes in the SWK Holdings portfolio after you announced the deal, and I'm just wondering if you could update us as to what the balance of their loans and the number of loans you expect to have coming over on April 6th is going to be. Sure. You know, subject to a little bit of modification, there'll be 13 loans with a fair value of around $235 million. There's equity in addition to that. There's an equity portfolio of some stock positions, warrants, and there are a couple of remaining royalties that will come across. Those are generally not yielding right now, or yielding very low. And the aggregate yield on that portfolio, the total portfolio is about 14%. The debt only portfolio is about 16%. Okay. Thank you for that. Greg, when you were answering the last question, at least to me, you were breaking up quite a bit. I don't know if you're on a speaker or what. I do have a question for you. If I was a member of the media, I would just ask you, when are you gonna mark the software portfolio at zero, right? Because that's what the media expectation is at this point in time. I did wanna ask, you have had one loan at the end of the Q3 that was marked at a reasonable discount to par, I think around 82%. When I read the Las Vegas Sun, I see that Circadence closed a new investment round and is talking about strong revenue growth. I was wondering if you could update us on that particular credit because it seems as though things may have turned for the better. Yeah. Hopefully this is better sound wise. Let me know if you need me to repeat anything. As you pointed out, Circadence did successfully close on an equity round as well as sign a substantial contract with the Department of Defense, which is two things in combination that we believe will lead to an increase in performance for them. It is one that we do continue to watch. All right, great. Thank you for taking my questions. Thank you. As a reminder, to ask a question at this time, please press star one one on your touchtone telephone. Our next question comes from the line of Rick Shane with JPMorgan. Your line is now open. Hey, guys. Thanks for taking my questions this afternoon. First, actually this is both related, when you guys announced the transaction, you announced the SWK transaction, you announced an accretion level from an NII per share perspective, I assume. Given the movements in the stock price and the relative performance, how should we be thinking about that? Are there any caps or collars on the equity component that you're providing the $75 million? Well, thanks, Rick. Thanks for the question, and welcome to your first earnings call with us. We're glad to have you as part of the coverage team. The amount of equity is set at $75.5 million. That won't change. The number of shares will change modestly, based on the calculation of NAV. There'll still be meaningful accretion. There is some accounting that happens that actually increases the NII contribution as the stock declines. It's kinda counterintuitive. It, in effect, increases the discount at which we're buying the portfolio. As I said, it's fixed in terms of the dollar amount. The share count just, you know, changes based on the NAV. Got it. Presumably, that means that the deal becomes more dilutive because you are giving more shares in order to provide the $75 million of stock compensation or consideration. That's correct. You know, we're talking about an insignificant change in terms of the change in NAV. If you look at the 12/31 NAV versus the 9/30 NAV, you know, it's 1%-ish. It's not a meaningful amount. It at least at the moment the preliminary calculations are that that will largely be offset by increase in the discount that we're purchasing at because of the decline on the stock price. Got it. Okay. Very helpful. Then, look, you guys have a history of repurchasing shares. You didn't repurchase shares this quarter. You mentioned the fact that you do see that as an attractive opportunity. I am curious if one of the considerations in terms of just forestalling that during the Q4 was the impact of the acquisition, and is that something that post-acquisition lifts and you guys will start to go back to the market and be repurchasing shares again? We've done that in the past, and you know, that is our plan to discuss that with the board. You know, if history repeats itself, I would think the board would view it and has consistently with the management team that it's a good use of capital. But we were not legally available with the pending acquisition. When we were under LOI, we could not use the stock repurchase program. When we had the N-14 pending, we could not use the stock repurchase program. In general, the first time we'd be able to do it would be two days after the closing. However, that's in our blackout period for Q1. The first time that we can be back in the market is probably the second week of May. As we look at capital allocation, it's a balancing act between new deals and the long-term you know core earnings power that brings to the table versus the immediate accretion from buying at such a discount. We recognize the financial impact to our shareholders on that. Got it. Okay, great. That's very helpful. That was kind of what I was trying to understand. Very briefly, last question. What is remaining under your repurchase authorization from before? It's effectively. There's a number, but we can't use it. We'll- Okay. Revisit the whole number, you know, come the end of April, early May when we have our board meeting, and we'll have, you know, much better details on the portfolio. I appreciate that. A lot of moving parts for the new guy. I appreciate it very much, guys. Thank you. No, that's all right. We appreciate the questions. Again, welcome. We're glad to have you on board. Thanks. Fun to be here. Thank you. Our next question comes from the line of Sean-Paul Adams with B. Riley Securities. Your line is now open. Hey, guys. On the merger, I understand that you guys have proxy deadlines in the shareholder meetings, but, you know, was there any reason that, you know, kind of prevented, you know, the mail outs from going out a little bit sooner in the quarter? Yeah. Nothing to do with us. Technically, the SEC has 30 days to respond to your filing, and we filed November 19th, which would have meant a December 19th date for, you know, the initial comments back. You know, unfortunately, with the shutdown and the backlog that the SEC had, and this was not a typical investment company to investment company transaction. It was the acquisition by an investment company of an operating company. I would say, you know, there was a little more to digest for the SEC, but the reality is it took 72 days to get the majority of the comments and 77 days for the last comments. They weren't particularly difficult, and we, you know, once we had them, we turned them and filed as quickly as possible. There are absolutely no underlying business issues. It was really just getting through the queue at the SEC. I have to say, once they gave us their comments and they recognized that we had a deadline embedded into the merger agreement, they were very good to work with and very attentive. Got it. Appreciate the call. Thank you. I'm currently showing no further questions at this time. I'd now like to turn the call back over to David Spreng for closing remarks. Great. Thank you, operator, and thank you all for joining us today. We look forward to discussing our Q1 2026 Financial Results with you in May. This concludes today's conference. Thank you for your participation. You may now disconnect.